フォン・ウィレブランド因子 (von Willebrand factor) は,抗血栓性介入の標的として用いられる
1Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla Calif. 92037.
Circulation
|December 1, 1992
まとめ
小さなタンパク質の断片は,フォン・ウィレブランド因子を遮断することができます.
科学分野:
- バイオケミストリー バイオケミストリー
- 血液学 ヘマトロジ
- 分子生物学は分子生物学である.
背景:
- フォン・ウィルブランド因子 (Von Willebrand factor) は,高剪定ストレス下での血小板血栓形成に不可欠な粘着性タンパク質です.
- 血小板血栓形成は,フォン・ウィルブランド因子と血小板受容体グリコプロテインIb-IX-VとIIb-IIIaの相互作用を伴う.
- グリコプロテインIb-IX-Vの相互作用により,血小板活性化が始まり,グリコプロテインIIb-IIIa経由で安定した結合の前提となる.
研究 の 目的:
- 小型の再結合断片が,フォン・ウィルブランド因子をグリコプロテインIbに結合させることを阻害する可能性を調査する.
- 抗血栓性治療の新たな選択的アプローチを探求する.
主な方法:
- von Willebrand因子の特定の機能領域をターゲットに設計された小さな再結合断片を使用し,グリコプロテインIbに結合します.
- これらの断片がフォン・ウィレブランド因子と血小板の相互作用に及ぼす抑制効果を評価した.
主要な成果:
- 小型の再結合断片が,フォン・ウィレブランド因子のグリコタンパク質Ibへの結合を効果的に阻害することが示された.
- この相互作用に責任を負うフォン・ウィレブランド因子内の特定の機能領域を特定しました.
結論:
- フォン・ウィレブランド因子-グリコタンパク質Ibの相互作用を標的とした小さな再結合断片は,有望な選択性抗血栓剤戦略を提供している.
- このアプローチは,血栓形成を予防するための新しい治療法につながる可能性があります.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Extrinsic and Intrinsic Pathways of Hemostasis
10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482


